Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2017-06-07 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于控股股东减持股份的公告
Transaction in Own Shares Classification · 95% confidence The document is a formal announcement regarding the reduction of shares held by the controlling shareholder of Shenzhen Xintai Pharmaceutical Co., Ltd. It details the number of shares reduced, the parties involved, compliance with regulatory requirements, and related shareholder commitments. The content focuses on the shareholder's shareholding changes and compliance with lock-up and disclosure rules. There is no financial performance data, earnings information, or management discussion. The document is a regulatory announcement about a shareholder's transaction in shares, specifically a reduction in holdings by a controlling shareholder. This fits the category of Transaction in Own Shares (POS), which covers company share buybacks or sales by shareholders, including controlling shareholders' share reductions.
2017-06-07 Chinese
关于控股股东减持股份的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the reduction of shares held by the controlling shareholder of Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the number of shares reduced, the parties involved, compliance with relevant regulations, and the shareholder's commitments. The content focuses on shareholding changes and related disclosures rather than financial results, management changes, or legal proceedings. It is not a full financial report, earnings release, or management discussion. The document is a formal disclosure of a significant shareholder's share reduction, fitting the category of Major Shareholding Notification.
2017-06-01 Chinese
关于第一期员工持股计划的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of the company's first employee stock ownership plan, including details about stock purchases made under the plan. It is a disclosure of an internal capital-related activity involving employee shareholding. The document is short (719 characters) and focuses on the update of a share purchase plan rather than a full financial report or regulatory certification. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as employee stock plans.
2017-06-01 Chinese
简式权益变动报告书
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report" or "Simplified Report on Changes in Shareholding". It is issued by Shenzhen Xinyi Tai Pharmaceutical Co., Ltd. and details the changes in shareholding by the controlling shareholder, including the number of shares held before and after the change, the method of change (block trades), and related legal and regulatory compliance statements. The document references Chinese securities laws and regulations specifically related to disclosure of equity changes. It does not contain financial statements, earnings data, or management discussion of financial results. It is a formal disclosure of shareholding changes by a major shareholder, consistent with notifications of major shareholding changes. Therefore, the document fits the category of "Major Shareholding Notification" (Code: MRQ). The document length and detail confirm it is the report itself, not just an announcement of a report publication or a certification. Confidence is high due to clear content and regulatory references.
2017-06-01 Chinese
关于第一期员工持股计划的进展公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the progress of the company's first employee stock ownership plan. It mentions previous board and shareholder meetings where the plan was approved and states the current status of account openings and that no stock purchases have been made yet. The document is short (659 characters) and serves as an update on the implementation progress rather than the plan itself or detailed financial data. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about the employee stock plan progress and does not contain financial statements or detailed report content.
2017-05-31 Chinese
关于限售股份上市流通的提示性公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the lifting of restrictions on the circulation of restricted shares (限售股份上市流通) for Shenzhen Salubris Pharmaceuticals Co., Ltd. It includes specifics about the number of shares being unlocked, the shareholders involved, their commitments, and the schedule for the shares to become tradable. The document references regulatory approvals and compliance with commitments by shareholders. It is not a financial report, earnings release, or management discussion, but rather a regulatory announcement about share circulation and shareholder commitments. This fits the category of a Regulatory Filing (RNS) as it is a formal regulatory announcement that does not fit into more specific categories like capital changes or director dealings, but is a compliance and disclosure document related to share circulation.
2017-05-24 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.